Furthermore, new drugs have been developed and are under confirmatory study, i.e., riluzole and edaravone [10,11], whose mechanism in ALS is uncertain, and tofersen, approved by the FDA in early 2023 for use by people with SOD1-related genetic ALS [12]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.